Skip to main contentAI and Advanced
/
ROSSARI · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
RO
NSE · Equity shares · Chemical Manufacturing2.30 · 0.53%
Rossari Biotech ROSSARI
NSE:INR 440.1
BSE:INR 444.95
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for ROSSARI
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 437.8
Day rangeINR 435.65 — INR 445.75
52-week rangeINR 372.9 — INR 746.05
Volume49,511
Market cap2,759.41
P/E19.3
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,396.37
Net Income (INR Cr)149.21
Rev Growth (5 Year %)27.57
EPS Growth (5 Year %)11.73
P/E Ratio19.3
EPS24.33
Research path: Interpret Rossari Biotech's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
ROSSARIRossari Biotech1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 2,288.79 | 1,896.18 | 1,572.15 |
| Accumulated Depreciation Total | -249.61 | -201.28 | -156.36 |
| Cash Equivalents | 30.05 | 0 | 13.1 |
| Other Liabilities Total | 8.26 | 5.26 | 3.98 |
| Accrued Expenses | 13.26 | 10.49 | 2.72 |
| Long Term Debt | 89.2 | 100.03 | 33.32 |
| Common Stock Total | 11.08 | 11.07 | 11.05 |
| Other Equity Total | -0.14 | -0.08 | Not available |
| Other Current Assets Total | 29.31 | 14.4 | 3.39 |
| Prepaid Expenses | 3.59 | 2.01 | 1.25 |
| Total Assets | 2,288.79 | 1,896.18 | 1,572.15 |
| Current Portof LT Debt/Capital Leases | 37.64 | 9.55 | 12.03 |
| Additional Paid-In Capital | 473.18 | 475.08 | 468.63 |
| Cash | 45.26 | 44.2 | 12.07 |
| Total Equity | 1,333.35 | 1,185.45 | 1,047.73 |
| Long Term Investments | 27.84 | 26.77 | 25.36 |
| Retained Earnings(Accumulated Deficit) | 849.23 | 699.37 | 568.05 |
| Total Common Shares Outstanding | 5.54 | 5.54 | 5.52 |
| Property/Plant/Equipment Total-Gross | 983.45 | 695 | 518.26 |
| Tangible Book Valueper Share Common Eq | 200.32 | 169.9 | 142.07 |
| Goodwill Net | 118.71 | 118.71 | 118.71 |
| Total Liabilities | 955.44 | 710.74 | 524.42 |
| Total Debt | 435.94 | 218 | 118.79 |
| Short Term Investments | 37.62 | 60.85 | 45.64 |
| Cashand Short Term Investments | 112.93 | 105.06 | 70.82 |
| Total Receivables Net | 592.62 | 515.57 | 462.51 |
| Notes Payable/Short Term Debt | 283.71 | 86.11 | 62.53 |
| Deferred Income Tax | 43.05 | 46.57 | 51.47 |
| Accounts Receivable-Trade Net | 557.56 | 474.79 | 425.29 |
| Property/Plant/Equipment Total-Net | 733.84 | 493.72 | 361.9 |
| Total Current Liabilities | 789.56 | 536.57 | 424.74 |
| Total Inventory | 505.23 | 406.1 | 306.82 |
| Accounts Payable | 323.45 | 286.34 | 219.1 |
| Other Currentliabilities Total | 131.49 | 144.08 | 128.36 |
| Total Long Term Debt | 114.58 | 122.34 | 44.23 |
| Intangibles Net | 105.2 | 126.1 | 144.15 |
| Other Long Term Assets Total | 25.75 | 17.75 | 8.21 |
| Note Receivable-Long Term | 33.77 | 70 | 69.04 |
| Total Current Assets | 1,243.68 | 1,043.14 | 844.79 |
| Capital Lease Obligations | 25.38 | 22.31 | 10.91 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.62
Price to Sale Ratio1.15
Margins
Operating Margin 12m8.3
Operating Margin 5y Avg9.11
Net Profit Margin 12m5.91
Net Profit Margin 5y6.58
Yield
Dividend Yield %0.1
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk42.31
Analyst consensus
ConsensusBuy
Consensus score1.80
Analyst opinions5
Strong Sell count0
Sell count0
Hold count1
Buy count2
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Asian Paints | INR 2,675.2 | 2.57 L | 58.09 | — |
| Solar Industries India | INR 18,890 | 1.71 L | 99.61 | — |
| Pidilite Industries | INR 1,577.1 | 1.61 L | 64.76 | — |
| SRF | INR 2,870 | 85,316.23 | 44.57 | — |
| Linde India | INR 6,897.45 | 58,824.36 | 110.53 | — |
Shareholding
Ownership
- Promoter
- 68.14%
- FII
- 2.03%
- MF
- 9.77%
- Other
- 20.06%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Earnings call transcript: Rossari Biotech posts record Q1 2026 revenue beat - Investing.com CanadaMarket news · 21 Jul 2026, 12:02 am
Earnings call transcript: Rossari Biotech posts record Q1 2026 revenue beat Investing.com Canada
Rossari Biotech declares dividend at 17th AGM - scanx.tradeMarket news · 20 Jul 2026, 11:35 pm
Rossari Biotech declares dividend at 17th AGM scanx.trade
Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March 2026 - marketscreener.comMarket news · 20 Jul 2026, 11:20 pm
Rossari Biotech Limited Approves Dividend for the Financial Year Ended 31 March 2026 marketscreener.com
ROSSARI: Record quarterly revenue and EBITDA, with margin improvement expected as B2C exits progress - TradingViewMarket news · 20 Jul 2026, 7:57 pm
ROSSARI: Record quarterly revenue and EBITDA, with margin improvement expected as B2C exits progress TradingView
Rossari Biotech Q1 FY27 slides: revenue surges 28% as margins compress - Investing.comMarket news · 20 Jul 2026, 7:29 pm
Rossari Biotech Q1 FY27 slides: revenue surges 28% as margins compress Investing.com
ROSSARI: Record quarterly revenue and EBITDA, with margin improvement expected as core business scales - TradingViewMarket news · 20 Jul 2026, 6:54 pm
ROSSARI: Record quarterly revenue and EBITDA, with margin improvement expected as core business scales TradingView
Corporate actions
Events
- annual General MeetingAGM
- board MeetingsQuarterly Results
- dividendRs.0.5000 per share(25%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Rossari Biotech
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Rossari Biotech Limited is an India-based company. The Company is engaged in the manufacturing, selling and distribution of specialty chemicals. Its products cater to global brands in the Fast Moving Consumer Goods (FMCG) sector and find applications in a host of consumer centric products and home and personal care products, textile chemicals, animal health and nutrition and cosmetic products. It operates through three segments: Home, Personal Care and Performance Chemicals (HPPC), Textile Specialty Chemicals (TSC), and Animal Health and Nutrition (AHN). The HPPC produces acrylic polymers. The TSC provides solutions for pre-treatment, dyeing and printing, finishing, and specialty chemicals for the textile industry. The AHN provides wellness solutions for pet animals and poultry, focusing on their health and performance. Its products include DETPRO 2040 CP, Rossblue, Amido Silicones, Rosselectro C, NEOBIND 7050 SC LIQUID, and others. Its flagship brand is Freshee.
Company facts
- Industry
- Chemical Manufacturing
- Sector
- Chemical Manufacturing
- NSE Code
- ROSSARI
- BSE Code
- 543213
Questions
Stock FAQ
What is the symbol and ISIN of Rossari Biotech?
Rossari Biotech has the symbol ROSSARI and ISIN - INE02A801020.
What is the current price of Rossari Biotech?
Rossari Biotech is currently trading at INR 440.10.
What are the year high and year low of Rossari Biotech?
Rossari Biotech has a year high of INR 746.05 and a year low of INR 372.90.
What is the market capitalization of Rossari Biotech?
Rossari Biotech has a market capitalization of INR 2,759.41 crore.
What is the P/E ratio of Rossari Biotech?
Rossari Biotech has a P/E ratio of 19.30.
What is the dividend yield of Rossari Biotech?
Rossari Biotech has a dividend yield of 0.10%.
How is the financial performance of Rossari Biotech based on revenue, net income, and EPS?
Rossari Biotech has revenue of INR 2,396.37 crore, net income of INR 149.21 crore, and EPS of INR 27.20.
What is the book value of Rossari Biotech?
Rossari Biotech has a book value of NA.
What is the debt-to-equity ratio of Rossari Biotech?
Rossari Biotech has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Rossari Biotech?
Rossari Biotech has a price-to-book ratio of NA and a price-to-sales ratio of 1.15.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.